BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | May 20, 2019
Finance

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri. On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million)...
BioCentury | May 9, 2019
Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

Polyphor halts Phase III enrollment of pneumonia therapy Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56%...
BioCentury | May 7, 2019
Financial News

Liver cell therapy company Promethera grows Asian investor base with D round

Belgian company Promethera added new Japanese and Korean investors in its series D round Monday, as part of its focus on growing its Asia network to leverage the "openness" to stem cell therapies in the...
BioCentury | Apr 19, 2019
Clinical News

Promethera's HepaStem cell therapy safe in liver failure study

Promethera said its HepaStem cell therapy comprising human adult liver-derived mesenchymal stem cells achieved a positive safety profile and improved three measures of liver disease severity in a Phase IIa trial to treat acute-on-chronic liver...
BioCentury | Oct 8, 2018
Company News

Management tracks: As Akcea shifts to commercialization, Crooke resigns from board

Akcea Therapeutics Inc. (NASDAQ:AKCA) said Stanley Crooke, founder, chairman and CEO of parent company Ionis Pharmaceuticals Inc. (NASDAQ:IONS), resigned from Akcea's board. Ionis CBO Damien McDevitt will take Crooke's place on Akcea's board. An Ionis...
BioCentury | Jun 30, 2018
Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...
BioCentury | Jun 22, 2018
Finance

Regenerating eastward

Having capitalized on the cell therapy expertise and manufacturing incentives of its European home base, Promethera Biosciences S.A. is expanding to Japan to tap the commitment to regenerative medicines among investors, pharmas and regulators. After...
BioCentury | Apr 13, 2018
Company News

Promethera acquires antibody play Baliopharm

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) said it acquired antibody developer Baliopharm AG (Basel, Switzerland). Promethera declined to disclose financial details. Promethera also raised €9.3 million ($11.4 million) on April 10 through the...
Items per page:
1 - 10 of 34
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | May 20, 2019
Finance

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri. On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million)...
BioCentury | May 9, 2019
Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

Polyphor halts Phase III enrollment of pneumonia therapy Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56%...
BioCentury | May 7, 2019
Financial News

Liver cell therapy company Promethera grows Asian investor base with D round

Belgian company Promethera added new Japanese and Korean investors in its series D round Monday, as part of its focus on growing its Asia network to leverage the "openness" to stem cell therapies in the...
BioCentury | Apr 19, 2019
Clinical News

Promethera's HepaStem cell therapy safe in liver failure study

Promethera said its HepaStem cell therapy comprising human adult liver-derived mesenchymal stem cells achieved a positive safety profile and improved three measures of liver disease severity in a Phase IIa trial to treat acute-on-chronic liver...
BioCentury | Oct 8, 2018
Company News

Management tracks: As Akcea shifts to commercialization, Crooke resigns from board

Akcea Therapeutics Inc. (NASDAQ:AKCA) said Stanley Crooke, founder, chairman and CEO of parent company Ionis Pharmaceuticals Inc. (NASDAQ:IONS), resigned from Akcea's board. Ionis CBO Damien McDevitt will take Crooke's place on Akcea's board. An Ionis...
BioCentury | Jun 30, 2018
Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...
BioCentury | Jun 22, 2018
Finance

Regenerating eastward

Having capitalized on the cell therapy expertise and manufacturing incentives of its European home base, Promethera Biosciences S.A. is expanding to Japan to tap the commitment to regenerative medicines among investors, pharmas and regulators. After...
BioCentury | Apr 13, 2018
Company News

Promethera acquires antibody play Baliopharm

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) said it acquired antibody developer Baliopharm AG (Basel, Switzerland). Promethera declined to disclose financial details. Promethera also raised €9.3 million ($11.4 million) on April 10 through the...
Items per page:
1 - 10 of 34